Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis

From IgE to Anti‐IgE: Where do we stand?

“…Patients' evaluation of efficacy of treatment was in favour of anti-IgE treatment (P ¼ 0.001). Twentyone percent of verum treated patients reported complete control of symptoms (vs. 2% of placebo treated), 59% estimated improvement (vs. 35%), and only 2% experienced worsening (vs. 13%) (68).…”

“…The results of the previous study (55) warranted further evaluation of the efficacy of anti-IgE therapy in SAR, utilizing higher anti-IgE doses (68).…”

“…In comparison to the study on SAR in adults (68), where 44% of patients were recruited less than 1 week and 10% of patients were recruited even after the start of the unexpectedly early pollen season, in the study in children, anti-IgE was already administered 45 days prior to the start of the birch pollen season. The main requirements for successful anti-IgE therapy of patients with SAR therefore may be concluded from the three SAR trials: (i) the dose regimen has to be adopted to personal body weight and IgE base levels; (ii) free IgE serum levels have to be reduced substantially; and (iii) start of the anti-IgE treatment has to be early enough and far enough in advance of the pollen season/allergen exposure.…”

Le récepteur de forte affinité pour l’IgE : leçons d’une analyse structurale

“…Dans l'une, le traitement n'a pas eu d'effet bénéfique, ce qui pourrait être dû à la persistance d'IgE dans le sérum [36]. Dans l'autre, au cours de laquelle une réduction de la concentration sérique d'IgE a été obtenue, une diminution significative des symptômes et de l'usage des antihistaminiques a été observée [37]. [3].…”

Untitled

“…Omalizumab efficacy has also been assessed by Adelroth et al 8 in moderate -severe birch pollen-induced SAR patients. Overall 251 patients were treated with either subcutaneous Omab or placebo groups in a 2:1 proportion; 300 mg was given every 3 weeks for 3 doses or every 4 weeks for 2 doses, based on the basal serum IgE levels.…”